In an interview with Consultant360, Paul B. Rosenberg, MD, discussed his team’s research on using dronabinol, a legal form of synthetic THC, to treat agitation in patients with Alzheimer disease. What...
In a 2024 review, the International Psychogeriatric Association introduces a systematic method to manage agitation in patients with Alzheimer disease. Take our quiz to test your knowledge on this...
A large cohort study found no significant association between migraines, their subtypes, or frequency and Parkinson disease (PD) risk in women 45 years and older, suggesting migraines may not contribute to...
In an interview with Consultant360, Paul B. Rosenberg, MD, discussed his team’s research on using dronabinol, a legal form of synthetic THC, to treat agitation in patients with Alzheimer disease. What...
In a 2024 review, the International Psychogeriatric Association introduces a systematic method to manage agitation in patients with Alzheimer disease. Take our quiz to test your knowledge on this...
A cohort study of more than 400,000 Medicaid enrollees tracked changes in autism prevalence over 9 years. Do you know how much the rate changed in that time? Take the quiz to test your knowledge!
In this video, Gautam Dantas, PhD, discusses the results of his study, which showed that altered gut bacteria may be an indicator of the earliest stages of Alzheimer disease. He also talks about whether...
In this video, Paul B. Rosenberg, MD, discusses his team’s research on using dronabinol, a legal form of synthetic THC, to treat agitation in patients with Alzheimer disease. The study found that dronabinol...
In this video, Kasia Rothenberg, MD, PhD, describes Alzheimer disease-related agitation, details the difficulty in testing for Alzheimer disease-related agitation, looks ahead to potential treatment options...
Jeff Cummings, MD, ScD; Carolyn Clevenger, DNP, RN, GNP-BC, FAANP, FGSA, FAAN; Tatyana Gurvich, PharmD, BCGP; Lakelyn Hogan Eichenberger, PhD, MA, MBA; W. Clay Jackson, MD, DipTh; Sean Tunis, MD, MSc; Kate Zhong, MD, MSc, FRCP
Agitation in Alzheimer’s dementia is a serious neuropsychiatric condition that is highly prevalent and underdiagnosed. It contributes to adverse clinical outcomes for people living with Alzheimer’s dementia...
Acetylcholinesterase inhibitors are frequently used in the treatment of Alzheimer disease due to their anti-inflammatory effects. But what is the potential of this class of medications to also impact the...
